Bioline RX Stock Price, News & Analysis (NASDAQ:BLRX)

$1.01 +0.01 (+1.00 %)
(As of 02/23/2018 03:42 AM ET)
Previous Close$1.00
Today's Range$1.00 - $1.03
52-Week Range$0.80 - $1.34
Volume168,800 shs
Average Volume714,544 shs
Market Capitalization$106.27 million
P/E Ratio-3.06
Dividend YieldN/A
Beta0.09

About Bioline RX (NASDAQ:BLRX)

Bioline RX logoBioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:BLRX
CUSIPN/A
Phone+972-8-6429100

Debt

Debt-to-Equity RatioN/A
Current Ratio10.12%
Quick Ratio10.12%

Price-To-Earnings

Trailing P/E Ratio-3.06060606060606
Forward P/E Ratio-4.04
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.61 per share
Price / Book1.66

Profitability

Trailing EPSN/A
Net Income$-15,840,000.00
Net MarginsN/A
Return on Equity-47.20%
Return on Assets-42.23%

Miscellaneous

Employees43
Outstanding Shares106,270,000

Bioline RX (NASDAQ:BLRX) Frequently Asked Questions

What is Bioline RX's stock symbol?

Bioline RX trades on the NASDAQ under the ticker symbol "BLRX."

How were Bioline RX's earnings last quarter?

Bioline RX Ltd (NASDAQ:BLRX) announced its earnings results on Thursday, August, 11th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.07). View Bioline RX's Earnings History.

When will Bioline RX make its next earnings announcement?

Bioline RX is scheduled to release their next quarterly earnings announcement on Thursday, March, 22nd 2018. View Earnings Estimates for Bioline RX.

Where is Bioline RX's stock going? Where will Bioline RX's stock price be in 2018?

4 brokerages have issued twelve-month target prices for Bioline RX's stock. Their predictions range from $3.00 to $4.00. On average, they expect Bioline RX's share price to reach $3.25 in the next year. View Analyst Ratings for Bioline RX.

What are Wall Street analysts saying about Bioline RX stock?

Here are some recent quotes from research analysts about Bioline RX stock:

  • 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (2/20/2018)
  • 2. Maxim Group analysts commented, "BiolineRx announced long-term follow-up data from the phase 2a study of BL-8040 (CXCR4 antagonist) in relapsed/refractory acute myeloid leukemia (r/ r AML) demonstrating improved overall survival (OS)." (12/4/2017)
  • 3. HC Wainwright analysts commented, "AML Needle Continues to Point in Right Direction; Reiterate Buy Responses appear to impact survival in relapsed or refractory setting. This morning, BioLineRx announced long-term follow-up data from the BL-8040 Phase 2a in relapsed or refractory AML. Recall that in March 2016, topline results (n=42) were presented showing an overall response rate (CR+CRi) of 38%, which compared favorably to a historical control of approximately 20% (HiDAC alone). With longer observation in hand, the company is highlighting data from 16 patients in the expansion phase of the study: 1) median follow-up time of 338 days (29-853 days); 2) median overall survival of 11.1 months; and 3) estimated one- and two-year survival rates of 37.5% and 28.5%, respectively. While these patient numbers continue to be small, they continue to compare favorably with the expected overall survival of 6.1 months for HiDAC." (12/4/2017)

Who are some of Bioline RX's key competitors?

Who are Bioline RX's key executives?

Bioline RX's management team includes the folowing people:

  • Aharon Schwartz, Chairman of the Board (Age 75)
  • Philip Adam Serlin, Chief Executive Officer (Age 57)
  • Mali Zeevi, Chief Financial Officer
  • Merril Gersten, Chief Scientific Officer
  • Moshe Phillip M.D., Vice President of Medical Affairs and Senior Clinical Advisor (Age 59)
  • David Malek, Vice President - Business Development (Age 35)
  • Leah Klapper, General Manager, BioLine Innovations Jerusalem (Age 1)
  • Michael J. Anghel, Director (Age 78)
  • Jacob Friedman, Director (Age 44)
  • Raphael Hofstein, Director (Age 63)

Who owns Bioline RX stock?

Bioline RX's stock is owned by a variety of of institutional and retail investors. Top institutional investors include NOVARTIS PHARMA AG (5.20%), NOVARTIS PHARMA AG (5.20%), Renaissance Technologies LLC (0.41%) and Deutsche Bank AG (0.26%). View Institutional Ownership Trends for Bioline RX.

Who sold Bioline RX stock? Who is selling Bioline RX stock?

Bioline RX's stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG. View Insider Buying and Selling for Bioline RX.

Who bought Bioline RX stock? Who is buying Bioline RX stock?

Bioline RX's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Bioline RX.

How do I buy Bioline RX stock?

Shares of Bioline RX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioline RX's stock price today?

One share of Bioline RX stock can currently be purchased for approximately $1.01.

How big of a company is Bioline RX?

Bioline RX has a market capitalization of $106.27 million. Bioline RX employs 43 workers across the globe.

How can I contact Bioline RX?

Bioline RX's mailing address is Modi'in Technology Park 2 HaMa'ayan Street, MODIIN, 7177871, Israel. The biotechnology company can be reached via phone at +972-8-6429100 or via email at [email protected]


MarketBeat Community Rating for Bioline RX (BLRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  430
MarketBeat's community ratings are surveys of what our community members think about Bioline RX and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bioline RX (NASDAQ:BLRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.25$3.20$3.20$2.85
Price Target Upside: 200.93% upside196.30% upside181.94% upside141.53% upside

Bioline RX (NASDAQ:BLRX) Consensus Price Target History

Price Target History for Bioline RX (NASDAQ:BLRX)

Bioline RX (NASDAQ:BLRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018HC WainwrightSet Price TargetBuy$4.00LowView Rating Details
12/21/2017OppenheimerInitiated CoverageBuy$3.00MediumView Rating Details
12/4/2017Maxim GroupSet Price TargetBuy$3.00LowView Rating Details
8/9/2017Roth CapitalSet Price TargetBuy$3.00LowView Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$3.00N/AView Rating Details
9/23/2016S&P Equity ResearchLower Price Target$1.24 -> $1.10N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Bioline RX (NASDAQ:BLRX) Earnings History and Estimates Chart

Earnings by Quarter for Bioline RX (NASDAQ:BLRX)

Bioline RX (NASDAQ BLRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2018        
11/21/2017Q3 2017($0.05)($0.07)ViewN/AView Earnings Details
8/8/20176/30/2017($0.05)($0.05)$0.01 millionViewListenView Earnings Details
5/25/20173/31/2017($0.05)($0.08)$0.01 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.08)($0.13)$0.02 millionViewN/AView Earnings Details
11/22/2016Q316($0.07)($0.08)ViewN/AView Earnings Details
8/11/2016Q216($0.07)($0.07)ViewListenView Earnings Details
5/17/2016Q116($0.08)($0.10)ViewListenView Earnings Details
3/10/2016Q415($0.06)($0.07)ViewListenView Earnings Details
11/16/2015Q315($0.08)($0.03)ViewListenView Earnings Details
8/20/2015Q215($0.10)($0.09)ViewListenView Earnings Details
5/18/2015Q115($0.10)($0.08)ViewListenView Earnings Details
4/13/2015Q4 2014($0.10)($0.11)ViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.02)ViewN/AView Earnings Details
8/6/2014Q214($0.09)($0.12)ViewN/AView Earnings Details
5/20/2014Q114($0.11)($0.01)ViewN/AView Earnings Details
3/17/2014($0.15)($0.20)ViewN/AView Earnings Details
11/13/2013($0.18)($0.20)ViewN/AView Earnings Details
8/6/2013Q213($0.02)ViewN/AView Earnings Details
5/7/2013($0.02)($0.20)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.29)($0.30)ViewN/AView Earnings Details
11/14/2012Q312($0.15)ViewN/AView Earnings Details
8/15/2012Q2 2012($0.25)($0.02)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.30)ViewN/AView Earnings Details
3/22/2012Q4 2011($0.30)ViewN/AView Earnings Details
11/29/2011Q3 2011($0.20)ViewN/AView Earnings Details
8/23/2011Q2 2011($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bioline RX (NASDAQ:BLRX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.05)($0.05)($0.05)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Bioline RX (NASDAQ:BLRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bioline RX (NASDAQ BLRX)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Bioline RX (NASDAQ BLRX) News Headlines

Source:
DateHeadline
Bioline RX Ltd (BLRX) Expected to Post Earnings of -$0.06 Per ShareBioline RX Ltd (BLRX) Expected to Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - February 21 at 9:20 PM
Bioline RX (BLRX) Upgraded to Hold at Zacks Investment ResearchBioline RX (BLRX) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - February 20 at 6:48 PM
Technical Perspectives on Biotech Stocks -- BioCryst Pharma, BioDelivery Sciences, BioLine Rx, and BioTime - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- BioCryst Pharma, BioDelivery Sciences, BioLine Rx, and BioTime - PR Newswire (press release)
www.prnewswire.com - February 20 at 8:13 AM
Bioline RX (BLRX) Downgraded by Zacks Investment ResearchBioline RX (BLRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 6 at 6:52 PM
Bioline RX (BLRX) vs. Aptose Biosciences (APTO) Critical ComparisonBioline RX (BLRX) vs. Aptose Biosciences (APTO) Critical Comparison
www.americanbankingnews.com - February 6 at 1:28 PM
BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13
finance.yahoo.com - February 6 at 8:49 AM
Bioline RX Ltd (BLRX) Expected to Announce Earnings of -$0.06 Per ShareBioline RX Ltd (BLRX) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - February 4 at 9:08 PM
Bioline RX Ltd (BLRX) Given Consensus Recommendation of "Buy" by AnalystsBioline RX Ltd (BLRX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 2 at 7:24 PM
BioLineRx (BLRX) Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival - StreetInsider.comBioLineRx (BLRX) Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival - StreetInsider.com
www.streetinsider.com - January 24 at 8:01 AM
Bioline RX (BLRX) Rating Increased to Hold at Zacks Investment ResearchBioline RX (BLRX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - January 23 at 6:44 PM
BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cellsBioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
finance.yahoo.com - January 23 at 5:30 PM
BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical StudiesBioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies
finance.yahoo.com - January 23 at 5:30 PM
Oppenheimer Weighs in on Bioline RX Ltds FY2022 Earnings (BLRX)Oppenheimer Weighs in on Bioline RX Ltd's FY2022 Earnings (BLRX)
www.americanbankingnews.com - January 18 at 11:32 PM
Bioline RX (BLRX) PT Set at $4.00 by HC WainwrightBioline RX (BLRX) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - January 17 at 11:26 PM
Bioline RX Ltd (BLRX) Given Consensus Recommendation of "Hold" by AnalystsBioline RX Ltd (BLRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 8 at 10:02 PM
Bioline RX (BLRX) Upgraded to Sell at ValuEngineBioline RX (BLRX) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - December 31 at 12:46 AM
Blog Exposure - BioLine Declares Initiation of Phase-3 GENESIS Trial in Stem-Cell Mobilization Therapy BL-8040Blog Exposure - BioLine Declares Initiation of Phase-3 GENESIS Trial in Stem-Cell Mobilization Therapy BL-8040
finance.yahoo.com - December 26 at 9:17 AM
UPDATE: BioLineRx Ltd. (BLRX) Reports Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous ... - StreetInsider.comUPDATE: BioLineRx Ltd. (BLRX) Reports Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous ... - StreetInsider.com
www.streetinsider.com - December 22 at 8:23 PM
Bioline RX (BLRX) Research Coverage Started at OppenheimerBioline RX (BLRX) Research Coverage Started at Oppenheimer
www.americanbankingnews.com - December 21 at 4:28 PM
Stock Update (NASDAQ:BLRX): Bioline RX Ltd Sets in Motion Phase 3 Trial for Stem Cell Mobilization Therapy BL-8040Stock Update (NASDAQ:BLRX): Bioline RX Ltd Sets in Motion Phase 3 Trial for Stem Cell Mobilization Therapy BL-8040
finance.yahoo.com - December 21 at 9:50 AM
BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma PatientsBioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
finance.yahoo.com - December 21 at 9:50 AM
 Analysts Anticipate Bioline RX Ltd (BLRX) Will Post Earnings of -$0.06 Per Share Analysts Anticipate Bioline RX Ltd (BLRX) Will Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - December 16 at 11:26 AM
Bioline RX Ltd (BLRX) Given Consensus Rating of "Hold" by AnalystsBioline RX Ltd (BLRX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 14 at 11:56 PM
BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY - PR Newswire (press release)BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY - PR Newswire (press release)
www.prnewswire.com - December 7 at 5:27 PM
BioLineRx (BLRX) Announces Positive Overall Survival Results From LT Follow-up of Phase 2a Trial in r/r AML - StreetInsider.comBioLineRx (BLRX) Announces Positive Overall Survival Results From LT Follow-up of Phase 2a Trial in r/r AML - StreetInsider.com
www.streetinsider.com - December 6 at 5:04 PM
BioLineRx Ltd. Hosts Investor Breakfast Meeting in NYBioLineRx Ltd. Hosts Investor Breakfast Meeting in NY
finance.yahoo.com - December 5 at 10:30 AM
Bioline RX (BLRX) PT Set at $3.00 by OppenheimerBioline RX (BLRX) PT Set at $3.00 by Oppenheimer
www.americanbankingnews.com - December 4 at 5:22 PM
Bioline RX (BLRX) Stock Rating Reaffirmed by Maxim GroupBioline RX (BLRX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - December 4 at 12:30 PM
Bioline RX (BLRX) Given a $4.00 Price Target at HC WainwrightBioline RX (BLRX) Given a $4.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 4 at 11:38 AM
BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AMLBioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
finance.yahoo.com - December 4 at 9:49 AM
BioLineRx Ltd. (BLRX) Expected to Announce Earnings of -$0.07 Per ShareBioLineRx Ltd. (BLRX) Expected to Announce Earnings of -$0.07 Per Share
www.americanbankingnews.com - November 28 at 5:14 AM
BioLineRx Ltd. (BLRX) Lowered to Sell at Zacks Investment ResearchBioLineRx Ltd. (BLRX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - November 27 at 8:26 PM
FY2021 Earnings Forecast for BioLineRx Ltd. Issued By Oppenheimer Holdings (BLRX)FY2021 Earnings Forecast for BioLineRx Ltd. Issued By Oppenheimer Holdings (BLRX)
www.americanbankingnews.com - November 23 at 10:35 PM
BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 ... - PR Newswire (press release)BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 ... - PR Newswire (press release)
www.prnewswire.com - November 21 at 3:33 PM
BioLineRx Reports Third Quarter 2017 Financial ResultsBioLineRx Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 21 at 3:33 PM
BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers SymposiumBioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium
finance.yahoo.com - November 20 at 5:51 PM
BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers SymposiumBioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium
finance.yahoo.com - November 20 at 5:51 PM
BioLineRx Ltd. (BLRX) Receives Average Recommendation of "Buy" from AnalystsBioLineRx Ltd. (BLRX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 19 at 8:02 PM
BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New YorkBioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York
finance.yahoo.com - November 16 at 12:04 PM
BioLineRx Ltd. (BLRX) Scheduled to Post Quarterly Earnings on TuesdayBioLineRx Ltd. (BLRX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 14 at 2:30 AM
BioLineRx to Report Third Quarter 2017 Results on November 21, 2017BioLineRx to Report Third Quarter 2017 Results on November 21, 2017
finance.yahoo.com - November 9 at 5:47 PM
Zacks: Analysts Anticipate BioLineRx Ltd. (BLRX) Will Post Earnings of -$0.05 Per ShareZacks: Analysts Anticipate BioLineRx Ltd. (BLRX) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - November 9 at 1:44 PM
BioLineRx Announces Oral Presentation at ASH of Data Supporting ... - PR Newswire (press release)BioLineRx Announces Oral Presentation at ASH of Data Supporting ... - PR Newswire (press release)
www.prnewswire.com - November 2 at 10:15 PM
BioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term EngraftmentBioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term Engraftment
finance.yahoo.com - November 2 at 5:14 PM
BioLineRx Ltd. (BLRX) Given Average Recommendation of "Buy" by BrokeragesBioLineRx Ltd. (BLRX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 25 at 9:34 PM
-$0.05 Earnings Per Share Expected for BioLineRx Ltd. (BLRX) This Quarter-$0.05 Earnings Per Share Expected for BioLineRx Ltd. (BLRX) This Quarter
www.americanbankingnews.com - October 20 at 8:30 PM
BioLineRx (BLRX) Says Genentech Commenced Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under ... - StreetInsider.comBioLineRx (BLRX) Says Genentech Commenced Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under ... - StreetInsider.com
www.streetinsider.com - October 18 at 10:54 PM
Head to Head Survey: BioLineRx (BLRX) and Its CompetitorsHead to Head Survey: BioLineRx (BLRX) and Its Competitors
www.americanbankingnews.com - October 18 at 10:22 PM
BioLineRx Ltd. (BLRX) Given a $4.00 Price Target by HC Wainwright AnalystsBioLineRx Ltd. (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - October 18 at 8:22 PM
BioLineRx Ltd. (BLRX) PT Set at $3.00 by Oppenheimer Holdings, Inc.BioLineRx Ltd. (BLRX) PT Set at $3.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 18 at 7:08 PM

SEC Filings

Bioline RX (NASDAQ:BLRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bioline RX (NASDAQ:BLRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bioline RX (NASDAQ BLRX) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.